IL2 and graft versus host disease: The systemic administration of inflammatory cytokines such as IL-2 induces severe side effects related to T lymphocyte proliferation and activation, i.e., severe graft-versus-host disease (GvHD) or proliferation of regulatory T cells that decreases the GvL effect [46, 47].